Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Individualised Lu-177-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Journal article
Authors A. Sundlov
K. Sjogreen-Gleisner
J. Svensson
M. Ljungberg
T. Olsson
Peter Bernhardt
J. Tennvall
Published in European Journal of Nuclear Medicine and Molecular Imaging
Volume 44
Issue 9
Pages 1480-1489
ISSN 1619-7070
Publication year 2017
Published at Institute of Clinical Sciences, Section for Oncology, Radiation Physics, Radiology and Urology, Department of Radiation Physics
Pages 1480-1489
Language English
Links doi.org/10.1007/s00259-017-3678-4
Keywords Lu-177-DOTATATE, Neuroendocrine, Dosimetry, PRRT, Renal function, receptor radionuclide therapy, radiolabeled somatostatin analog, toxicity, y-90-dotatoc, octreotate, survival, cancers, Radiology, Nuclear Medicine & Medical Imaging
Subject categories Clinical Medicine

Abstract

Purpose To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). Method Treatment was given with repeated cycles of 7.4 GBq 177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging). All patients received treatment up to a renal BED of 27 +/- 2 Gy (alpha/beta = 2.6 Gy) (Step 1). Selected patients were offered further treatment up to a renal BED of 40 +/- 2 Gy (Step 2). Renal function was followed by estimation and measurement of the glomerular filtration rate (GFR). Results Fifty-one patients were included in the present analysis. Among the patients who received treatment as planned, the median number of cycles in Step 1 was 5 (range 3-7), and for those who completed Step 2 it was 7 (range 5-8); 73% were able to receive >4 cycles. Although GFR decreased in most patients after the completion of treatment, no grade 3-4 toxicity was observed. Patients with a reduced baseline GFR seemed to have an increased risk of GFR decline. Five patients received treatment in Step 2, none of whom exhibited a significant reduction in renal function. Conclusions Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?